Stockreport

Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF with relapsed or refractory Waldenström macroglobulinemia, with mostly low-grade side effects supporting further development. This early signal suggests Nurix's target [Read more]